Sandrine Vendeville, Franck Amblard, Leda Bassit, Leonid N. Beigelman, Lawrence M. Blatt, Xiaoyuan Chen, Lang Chou, Dieudonné Buh Kum, Sushmita Chanda, Jerome Deval, Xiu Geng, Kusum Gupta, Andreas Jekle, Haiyang Hu, Xiaojuan Hu, Hyunsoon Kang, Cheng Liu, Jyanwei Liu, David C. McGowan, Dinah L. Misner, Pierre Raboisson, Abel Acosta Sanchez*, Vladimir Serebryany, Antitsa D. Stoycheva, Julian A. Symons, Hua Tan, Hannah Vanrusselt, Caroline Williams, Michael Welch, Liangliang Zhang, Qingling Zhang, Yafeng Zhang, Raymond F. Schinazi, David B. Smith, and Yannick Debing
Journal of Medicinal Chemistry, Article ASAP 2024, published November 22, 2024 – DOI: 10.1021/acs.jmedchem.4c01814
Abstract:
Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination. GLP-26 is a potent CAM, which in this work was optimized for potency, safety, and other drug-like properties leading to ALG-001075. ALG-001075 was further advanced through clinical development as the highly soluble prodrug ALG-000184. ALG-000184 is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed, making ALG-000184 a promising candidate to become a cornerstone for future chronic suppressive and combination treatment regimens for CHB.
* author from Novalix